Stock Price

Digital asset firm Streamex appoints NYU's Anthony Marciano, signaling a strategic push for institutional credibility and M&A amid financial headwinds.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Nasdaq-listed Zeta Network Group is exploring real-world asset tokenization, signaling a pivotal move beyond Bitcoin for institutional treasury management.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

The firm's assets grew on market gains, but significant client outflows and shrinking fees triggered a sharp stock drop, revealing key industry pressures.

VENU closes a $13M deal for its first indoor venue, bringing an innovative fractional ownership "FireSuite" concept to the Denver area.

Automotive seating giant Adient boosts its 2026 forecast, banking on strong North American production and operational gains, despite a reported net loss.

With a key cancer drug awaiting FDA review and pivotal data imminent, Celcuity faces investors at a critical juncture. What will they be looking for?

The real estate giant's mixed cash and stock distribution reveals a strategy to fuel growth amid a nearshoring frenzy, impacting investors and the market.

Whitecap Resources adds financial heavyweight Scott Althen to its board as Craig Bryksa departs, signaling a new phase of governance after its massive Veren merger.

Atlanticus Holdings Corp. confirms its quarterly preferred stock dividend, highlighting a rare blend of FinTech innovation with reliable investor returns.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

With major acquisitions complete, Huntington's leadership will face investors to outline their vision for growth amid a complex economic landscape.

Creator commerce firm Amaze Holdings cancels a special meeting on a crucial stock dilution vote, raising questions about shareholder support and strategy.

As Erie prepares its 2025 results, investors eye underwriting profit, premium growth, and future guidance in a turbulent insurance market.

As PHINIA preps for its NYSE Investor Day, it plans to prove its value by balancing legacy engine tech with bold investments in a lower-carbon future.

S&P Global unveils 'Mobility Global' for its auto data spin-off, aiming to dominate the $30B market despite a sharp one-day drop in its stock price.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.